Published in Antimicrob Agents Chemother on April 01, 1988
New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother (1989) 2.63
In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother (1988) 1.89
In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother (1995) 1.60
Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay. Antimicrob Agents Chemother (1991) 1.37
The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob Agents Chemother (1997) 1.30
Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother (1992) 1.15
In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimicrob Agents Chemother (1989) 1.10
Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob Agents Chemother (1992) 1.09
Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother (1991) 1.06
In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob Agents Chemother (1990) 0.98
Effectiveness of spiramycin for treatment of congenital Toxoplasma gondii infection in rhesus monkeys. Antimicrob Agents Chemother (1994) 0.88
Pharmacokinetics of spiramycin in the rhesus monkey: transplacental passage and distribution in tissue in the fetus. Antimicrob Agents Chemother (1994) 0.86
In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother (1993) 0.83
Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice. Antimicrob Agents Chemother (1991) 0.82
Toxoplasma gondii: susceptibility and development of resistance to anticoccidial drugs in vitro. Antimicrob Agents Chemother (1993) 0.81
The new macrolides. Azithromycin and clarithromycin. West J Med (1994) 0.77
Prevention of Pneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients. Infection (1995) 0.75
Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science (1948) 19.46
A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther (1949) 13.89
Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg (1985) 5.91
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother (1986) 4.51
Congenital toxoplasmosis. A prospective study of 378 pregnancies. N Engl J Med (1974) 4.45
In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs. Antimicrob Agents Chemother (1983) 3.70
In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1984) 3.45
Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. J Exp Med (1979) 2.93
Specific labeling of intracellular Toxoplasma gondii with uracil. J Protozool (1977) 2.53
Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin. Antimicrob Agents Chemother (1981) 2.31
The RNA of toxoplasma gondii. Proc Soc Exp Biol Med (1970) 1.93
Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother (1987) 1.91
Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med (1987) 1.89
A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen. J Immunol Methods (1979) 1.87
[Spiramycin therapy of experimental toxoplasmosis in mice]. Presse Med (1958) 1.73
Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice. Antimicrob Agents Chemother (1986) 1.59
A rapid micro method for the simultaneous determination of phagocytic-microbiocidal activity of human peripheral blood leukocytes in vitro. J Immunol Methods (1977) 1.57
Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy. Am J Trop Med Hyg (1987) 1.56
Effect of roxithromycin on acute toxoplasmosis in mice. Antimicrob Agents Chemother (1987) 1.28
Acute toxoplasmosis. Effective treatment with pyrimethamine, sulfadiazine, leucovorin calcium, and yeast. JAMA (1960) 1.24
Plaque assay of Toxoplasma on monolayers of chick embryo fibroblasts. Proc Soc Exp Biol Med (1959) 1.16
Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro. Antimicrob Agents Chemother (1986) 1.11
Macrophages. Methods Enzymol (1979) 1.10
Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. J Parasitol (1975) 1.09
Induction of interferon in mice infected with Toxoplasma gondii. Proc Soc Exp Biol Med (1966) 1.07
Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother (1987) 1.02
In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice. Eur J Clin Microbiol (1987) 1.01
[Spiramycin ; therapeutic value in humans. (author's transl)]. Sem Hop (1982) 1.00
In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii. Antimicrob Agents Chemother (1987) 0.99
Tissue distribution of roxithromycin. J Antimicrob Chemother (1987) 0.87
Biochemical basis for the selective toxicity of erythromycin. Biochem Pharmacol (1970) 0.79
[Curative activity of spiramycin adipate by parenteral route in experimental septicemia in mice. Comparison with orally administered basic spiramycin]. Pathol Biol (Paris) (1986) 0.78
Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol (1997) 5.91
Swarming of Pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili. J Bacteriol (2000) 4.59
Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother (1989) 2.30
Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol (1999) 1.96
In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother (1986) 1.71
Activity of ten antimicrobial agents against anaerobic bacteria. J Antimicrob Chemother (1978) 1.66
Cellular events and intracellular survival of Campylobacter jejuni during infection of HEp-2 cells. Infect Immun (1989) 1.65
Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (1992) 1.62
Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother (1987) 1.62
Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology (1990) 1.61
A plasmid-mediated cephalosporinase from Achromobacter species. J Infect Dis (1982) 1.55
Contribution of beta-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in Enterobacter cloacae. Antimicrob Agents Chemother (1987) 1.55
Treatment of vascular graft infection by in situ replacement with a rifampin-bonded gelatin-sealed Dacron graft. J Vasc Surg (1994) 1.51
Expression of host resistance to Salmonella typhi and Salmonella typhimurium: bacterial survival within macrophages of murine and human origin. Microb Pathog (1990) 1.42
Effect of motility and chemotaxis on the invasion of Salmonella typhimurium into HeLa cells. Microb Pathog (1990) 1.38
Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother (2003) 1.33
Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J Int Med Res (1996) 1.33
Identification of Campylobacter jejuni surface proteins that bind to Eucaryotic cells in vitro. Infect Immun (1990) 1.32
Combination therapy: a way to limit emergence of resistance? Am J Med (1986) 1.30
Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1991) 1.24
Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis (2001) 1.22
Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae. Antimicrob Agents Chemother (1991) 1.16
Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate. J Antimicrob Chemother (1990) 1.13
Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice. J Antimicrob Chemother (1988) 1.12
In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimicrob Agents Chemother (1989) 1.10
Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother (1991) 1.06
Effect of mucin on Campylobacter jejuni association and invasion on HEp-2 cells. Microb Pathog (1988) 1.05
Development of beta-lactam-resistant Enterobacter cloacae in mice. J Infect Dis (1987) 1.04
Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother (1994) 1.02
In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob Agents Chemother (1990) 0.98
C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob Agents Chemother (2001) 0.97
Activity of minocycline against Toxoplasma gondii infection in mice. J Antimicrob Chemother (1991) 0.96
Bacterial antibiotic efflux systems of medical importance. Cell Mol Life Sci (1999) 0.95
Fish oil decreases natural resistance of mice to infection with Salmonella typhimurium. Metabolism (1992) 0.95
Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species. Antimicrob Agents Chemother (1989) 0.95
Hydrolysis of Cefotaxime by a beta-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother (1980) 0.94
Genetic background of attenuated Salmonella typhimurium has profound influence on infection and cytokine patterns in human dendritic cells. J Leukoc Biol (2001) 0.94
[Serum, lymph node and testicular concentrations of penicillin in 31 healthy or syphilitic rabbits treated with penicillin]. Pathol Biol (Paris) (1971) 0.93
Respective role of polymorphonuclear leukocytes and their integrins (CD-11/18) in the local or systemic toxicity of lipopolysaccharide. J Leukoc Biol (1993) 0.93
Comparative study of the beta-lactamase activity found in Achromobacter. Can J Microbiol (1983) 0.91
Arteether, a qinghaosu derivative, in toxoplasmosis. Trans R Soc Trop Med Hyg (1988) 0.91
Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients. Antimicrob Agents Chemother (1976) 0.90
Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft. Ann Vasc Surg (1991) 0.90
Macrophage oxidative metabolism and intracellular Toxoplasma gondii. Microb Pathog (1989) 0.90
Newly documented antimicrobial activity of quinolones. Eur J Clin Microbiol Infect Dis (1991) 0.89
Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J Antimicrob Chemother (1990) 0.89
Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother (1986) 0.87
In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli. Infection (1994) 0.87
Usual and unusual antibacterial effects of quinolones. J Antimicrob Chemother (1990) 0.86
Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora. A double-blind study. Drugs (1988) 0.85
Laboratory survey of fluoroquinolone activity. Rev Infect Dis (1989) 0.83
[Evolution of gentamicin sensitivity in acute postpartum staphylococcal endocarditis]. Ann Med Interne (Paris) (1972) 0.83
Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection. J Antimicrob Chemother (1988) 0.83
Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia. J Antimicrob Chemother (1987) 0.83
Overexpression, refolding, and purification of the histidine-tagged outer membrane efflux protein OprM of Pseudomonas aeruginosa. Protein Expr Purif (2001) 0.82
Postantibiotic effect and host-bacteria interactions. J Antimicrob Chemother (1995) 0.82
Treatment of vascular graft infection by in situ replacement with cryopreserved aortic allografts: an experimental study. J Vasc Surg (1998) 0.81
Salmonella typhimurium thyA mutants fail to grow intracellularly in vitro and are attenuated in mice. Microbiology (2001) 0.80
Anaerobic bacteria: evaluation of disc susceptibility to four cephalosporins. Infection (1978) 0.80
In-vitro toxoplasmacidal activity of cationic electron carriers. J Antimicrob Chemother (1989) 0.80
Open study of ceftazidime in serious infections due to multiply-resistant bacteria. J Antimicrob Chemother (1983) 0.79
How predictable is development of resistance after beta-lactam therapy in Enterobacter cloacae infection? J Antimicrob Chemother (1989) 0.79
Beta-lactamases: clinical and genetic perspectives. J Antimicrob Chemother (1983) 0.79
Activity of roxithromycin against Toxoplasma gondii in murine models. J Antimicrob Chemother (1987) 0.78
Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants. J Antimicrob Chemother (1992) 0.78
Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother (1994) 0.78
Experimental treatment of vascular graft infection due to Staphylococcus epidermidis by in situ replacement with a rifampin-bonded polyester graft. Ann Vasc Surg (2001) 0.78
Permeability and penicillin-binding protein alterations in Salmonella muenchen: stepwise resistance acquired during beta-lactam therapy. Antimicrob Agents Chemother (1989) 0.78
Dietary supplementation with fish oil enhances in vivo synthesis of tumor necrosis factor. Immunol Lett (1992) 0.77
Serum levels of ciprofloxacin after single oral doses in patients with septicemia. Eur J Clin Microbiol Infect Dis (1989) 0.77
[Encephalogram changes in common manifestations of herpetic primoinfection]. Ann Med Interne (Paris) (1969) 0.77
Activity of amphotericin B and intraconazole against intraphagocytic Candida albicans. Eur J Clin Microbiol Infect Dis (1990) 0.76
Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology (1999) 0.76
Rifampicin loading of vascular grafts. J Antimicrob Chemother (1996) 0.75
Relative beta-lactamase- and transpeptidase-inhibitory activities of the new quinolone WIN-57273 in Staphylococcus aureus. Antimicrob Agents Chemother (1992) 0.75
[Initial results of treament with rifampicin of some septicemic states, 4 of which with endocarditis]. Bull Mem Soc Med Hop Paris (1968) 0.75
Restrictive antibiotherapy after renal transplantation. Can Med Assoc J (1979) 0.75
Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Int J Antimicrob Agents (1999) 0.75
[Current aspects of bacterial genetics: genotypic variations]. Gaz Med Fr (1965) 0.75
New strategies against an old plague: genetically engineered tuberculosis vaccines. Schweiz Med Wochenschr (2000) 0.75
[The role of cephalosporins in beta-lactam antibiotics. Mode of action. Concept of pharmacokinetics]. Rev Prat (1988) 0.75
[Streptococcal septicemia (excluding Osler's endocarditis)]. Rev Prat (1977) 0.75
[Is it possible to recognize aminoglycoside ototoxicity early using evoked potentials?]. Ann Med Interne (Paris) (1980) 0.75
Experimental colonization of vascular grafts with Staphylococcus aureus. Can J Surg (1983) 0.75
[Morbidity, mortality and etiology of gas gangrene in Canada]. Union Med Can (1981) 0.75
Two-dimensional polyacrylamide gel electrophoresis isolation and microsequencing of Pseudomonas aeruginosa proteins. Enzyme Protein (1993) 0.75
Sch 29482: stability and inhibitory potency towards beta-lactamases from Gram-negative bacteria. J Antimicrob Chemother (1982) 0.75
Does incubator noise increase risks of aminoglycoside ototoxicity? Audiology (1984) 0.75
[Experimental bacterial colonization of 3 types of arterial prosthesis]. Chirurgie (1983) 0.75
[Compounds of the beta-lactam group as inhibitors of beta-lactamases]. Rev Prat (1982) 0.75
[Lincosamides]. Pathol Biol (Paris) (1986) 0.75
[Scientific French in free-fall]. Union Med Can (1981) 0.75
Examination of enteropathogens for production of immunoglobulin A1 protease. Eur J Clin Microbiol (1985) 0.75
[Abdominal suppurations: point of view of an infectious disease specialist]. Ann Chir (1985) 0.75
[Beta-lactams: present status and perspectives]. Presse Med (1984) 0.75
[Active efflux. A disquieting bacterial resistance phenomenon]. Presse Med (1997) 0.75
"Chance makes a football of man's life". Infect Control Hosp Epidemiol (2000) 0.75
Phagocytes, antibiotics and intracellular parasites: are the experimental data clinically relevant? Eur J Clin Microbiol Infect Dis (1991) 0.75
Prevention: toward a golden age. Infect Control Hosp Epidemiol (1998) 0.75
[New antibacterial vaccinal strategies]. Presse Med (1996) 0.75